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Subacute thyroiditis (SAT) is a self-limiting thyroid
disease associated with a triphasic clinical course of
hyperthyroidism, hypothyroidism, and return to normal
thyroid function. The well-known clinical features of SAT
include thyroid pain with symptoms of hyperthyroidism,
suppressed level of thyroid-stimulating hormone (TSH),
low thyroid uptake of radioactive iodine, and elevated
erythrocyte sedimentation rate [1,2]. Diagnosis is based on
clinical and laboratory data, and tissue diagnosis is rarely
required [1,3,4]. We present the case of a 25-year-old
female with sudden onset of neck pain on the left side and
swelling 2 days after she received an influenza vaccine
injection of Vaxigrip®. Tracing back her history, she had
experienced the same symptoms when she was 12 years
old and recovered spontaneously. Therefore, we strongly
suspected that SAT was possibly associated with influenza
vaccine (Vaxigrip®) in this case.
SUBACUTE THYROIDITIS FOLLOWING INFLUENZA
VACCINE (VAXIGRIP®) IN A YOUNG FEMALE
Jeng-Yueh Hsiao, Shih-Chieh Hsin, Ming-Chia Hsieh, Pi-Jung Hsia, and Shyi-Jang Shin
Department of Endocrinology and Metabolism, Kaohsiung Medical University Chung-Ho
Memorial Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Subacute thyroiditis (SAT), also called de Quervain thyroiditis or granulomatous thyroiditis, is a self-
limiting, possibly viral, and inflammatory thyroid disorder that is usually associated with thyroid
pain and systemic symptoms. This report details a case of SAT possibly associated with influenza
vaccine (Vaxigrip®) in a young female. The diagnosis, therapeutic management and outcome are
discussed.
Key Words: subacute thyroiditis, de Quervain thyroiditis, influenza vaccine
(Kaohsiung J Med Sci 2006;22:297–300)
Received: August 10, 2005 Accepted: February 9, 2006
Address correspondence and reprint requests to: Dr Shyi-Jang Shin,
Department of Endocrinology and Metabolism, Kaohsiung Medical
University Chung-Ho Memorial Hospital, 100 Tzyou 1st Road,
Kaohsiung 807, Taiwan.
E-mail: sjshin@kmu.edu.tw
CASE REPORT
A 25-year-old female suffering from fever, left neck swelling,
and tender bulging mass for 3 days visited our clinic. Her
body temperature ranged from 37 to 39°C. There were no
chills, sore throat, cough, shortness of breath or chest pain,
and no genitourinary symptoms. Two days before this
episode of fever and subsequent development of a small,
tender bulging neck mass, which progressively enlarged,
she had received influenza vaccine (Vaxigrip®). Tracing
back her history, at 12 years of age, she had experienced a
similar episode from which she recovered spontaneously,
but she had not received any vaccination at that time.
On physical examination, her body temperature was
38°C, pulse rate was 90 bpm, respiratory rate was 15 breaths/
min, and blood pressure was 110/70 mmHg. Her sclera
was anicteric, pharynx was noninjected, and neck was
supple. There was no cervical lymphadenopathy. Heart
sounds were regular without murmurs, rubs or gallops.
Her breathing sounds were clear. There was no skin rash
and neurologic examination results were normal. A chest
radiograph showed normal results.
Routine laboratory tests were unremarkable except for
an erythrocyte sedimentation rate of 53 mm/hour (normal,
0–10 mm/hour). The leukocyte count was 9,790/μL (normal,
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4,000–11,000/μL) and C-reactive protein level was 14 μg/
mL (normal, < 5 μg/mL). Urinalysis showed normal results.
Blood culture results were negative. Thyroid function test
results were normal (total T4, 8.2 μg/dL; total T3, 85 ng/dL;
TSH, 1.0 μU/mL). Microsomal and thyroglobulin anti-
body test results were negative. Thyroid echocardiography
showed a hypoechogenic area over the left lobe (Figure 1).
Multinuclear giant cell granulomas were observed in a
fine-needle aspiration biopsy of the thyroid (Figure 2). The
patient became afebrile during the next week, while receiv-
ing nonsteroidal anti-inflammatory drugs and steroids
and recovered 2 weeks later. The tender neck mass also
disappeared. According to the clinical manifestations, SAT
was diagnosed. Since there was no viral infection prior to
this episode and fever had occurred just after influenza
vaccination, we suspected that this episode of SAT was
associated with the administration of influenza vaccine.
DISCUSSION
SAT has been termed granulomatous giant cell or de
Quervain’s thyroiditis. It is characterized by a generally
self-limiting, usually painful inflammatory lesion of the
thyroid gland, most probably of viral origin [5]. Many
viruses have been implicated, including mumps,
Coxsackie, influenza, adenoviruses, and echoviruses
[6–8]. All current evidence indicate that SAT is not an
autoimmune disease. The peak incidence occurs at 30–50
years of age, and women are affected thrice more frequently
than men [3,9].
SAT begins with a prodrome of generalized myalgias,
pharyngitis, low-grade fever and fatigue. Patients then
present with fever and severe neck pain, swelling, or both.
Painful SAT, which is a self-limiting inflammatory disor-
der, is the most common cause of thyroid pain [10]. A viral
cause of SAT has, therefore, been proposed, but clear evi-
dence is still lacking [7].
The hallmark of painful SAT is a markedly elevated
erythrocyte sedimentation rate. C-reactive protein con-
centration is similarly elevated [11]. Color-flow Doppler
ultrasonography may also help to make this distinction; in
patients with Graves’ disease, the thyroid gland is hyper-
vascular, whereas in patients with painful SAT, the gland
is hypoechogenic and has low-to-normal vascularity [12].
The treatment for painful SAT is to provide symptom-
atic relief only. Nonsteroidal medications or salicylates
are adequate to control mild thyroid pain; high doses
of glucocorticoids (e.g. 40 mg/day prednisone) provide
immediate relief. The doses of steroid should be tapered
over a period of 4–6 weeks [13].
SAT, which is considered to be a viral disease [6–8],
rarely recurs after a complete recovery, possibly because of
immunity to the offending virus. However, late recurrence
after several years has been reported [14–17]. The recurrent
episodes were similar to the first episode of SAT. The titers
of various viral antibodies were not increased during the
clinical course of recurrence [17].
If vaccination is performed with heterologous antigens
that are sufficiently different to permit an immunologic
response, but are sufficiently similar to react with autologous
antigens, then the vaccinated antigen may induce various
immune response and systemic symptoms such as fever
and myalgia. We report in this case that SAT occurred just
after influenza vaccination and without a recent episode of
viral infection before SAT. The patient had experienced a
similar episode of fever and tender neck mass at 12 years of
age, so SAT could be a possible diagnosis for that episode.
Figure 1. Thyroid ultrasonography showed a hypoechogenic area over
the left lobe of the thyroid gland (arrow).
Figure 2. Subacute thyroiditis: multinuclear giant cell granulomas
were observed in a fine-needle aspiration biopsy of the thyroid (arrow)
(Liu stain, 100×).
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The recurrent episode is thought possibly to have
been induced by the influenza vaccine injection due to
delayed hypersensitivity reactions with sensitized lymph-
oid cells.
The side effects of and adverse reactions to influenza
vaccine (Vaxigrip®) [18,19] that occurred during clinical
tr ia ls  were  erythema,  redness ,  swel l ing,  pain ,
ecchymosis and induration. The most frequent side
effect of vaccination is soreness at the vaccination site
(affecting 10–64% patients) that lasts < 2 days. Systemic
reactions included fever, malaise, myalgia, headache,
shivering, sweating, muscular pain and joint pain.
These reactions begin 6–12 hours after vaccination and
can persist for 1–2 days. No clinical case report to date
has demonstrated an association between SAT and
influenza vaccination.
In the Minnesota cohort study [20], the inclusion criteria
for diagnosis of SAT were any one of the following: (1)
painful thyroid and either suppressed uptake of 131I or
elevated erythrocyte sedimentation rate, or both; (2)
unilateral thyroid pain with abnormally low uptake of 131I
and elevated erythrocyte sedimentation rate; and (3)
pathologic diagnosis (surgical specimen or biopsy). In our
case, the patient presented with fever, left neck swelling,
and tender bulging mass. In addition, markedly elevated
erythrocyte sedimentation rate was observed. These findings
were consistent with a diagnosis of SAT. As there was no
evidence of recent bacterial or viral infection prior to this
episode and because fever had occurred just after influenza
vaccination, we highly suspected this episode of SAT to be
directly associated with the influenza vaccine or that the
recurrence was aggravated by influenza vaccination, but
more precise methods are required to determine this
possibility.
This case was a rare clinical case. Other researchers [21,
22] compiled and analyzed safety data on the inactivated
split influenza vaccine, Vaxigrip®, from 28 clinical trials
(total: 4,599 subjects aged 6 months to 99 years) to provide
a robust estimate of the reactogenicity profile. The most
frequent solicited reactions were nonsevere injection site
pain and erythema in children, adults and the elderly.
Mild or moderate fever was the most frequent reaction
among 6- to 36-month-old individuals; few systemic
reactions were reported in older groups. Reactogenicity
was comparable in healthy and high-risk children. The
long-term experience with the world’s most widely used
influenza vaccine, Vaxigrip®, confirms its excellent
tolerability, and its continued use in clinical practice
worldwide is supported.
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